Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF, or AC Adjuvant Chemotherapy

A Randomized Trial of Antiestrogen Therapy versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women

A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen

The Influence of Letrozole on Bone Mineral Density in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen -- a Companion Study to MA.17

The Influence of Letrozole on Serum Lipid Concentrations in Women with Primary Breast Cancer Who Have Completed Five Years of Adjuvant Tamoxifen -- A Companion Study to MA.17

A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)

A Phase III Study of Regional Radiation Therapy in Early Breast Cancer

A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer

A Phase I/II Study of Increasing Doses of Epirubicin and Docetaxel Plus Pegfilgrastim for Locally Advanced Or Inflammatory Breast Cancer

A Randomized Three-Arm Multi-Centre Comparison of 1 Year and 2 Years of Herceptin versus no Herceptin in Women With HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy

Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary nodes

Phase III Trial of Observation +/- Tamoxifen Vs. Rt +/- Tamoxifen For Good Risk Duct Carcinoma In-Situ (DCIS) of The Female Breast

A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer - A Companion Study to MA.27

A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients with T1c-T3 Operable Carcinoma of the Breast.

A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast

Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

Cooperative Clinical Trial of Intensive CEF versus Standard CMF as Adjuvant Therapy for Breast Carcinoma in Premenopausal Patients With Histologically Involved Axillary Nodes

A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer

The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer - A Companion Study to MAP.3

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
BREAST	MA12	698	522	566	571
BREAST	MA14	667	407	361	514
BREAST	MA17	5187	873	564	1081
BREAST	MA17B	226	0	0	0
BREAST	MA17L	347	0	0	0
BREAST	MA17R	1918	280	59	316
BREAST	MA20	1832	1138	938	1292
BREAST	MA21	2104	1203	1488	1488
BREAST	MA22	93	41	40	41
BREAST	MA24	160	6	0	6
BREAST	MA25	3	2	1	2
BREAST	MA26	26	5	2	7
BREAST	MA27	7576	3920	4029	4354
BREAST	MA27B	497	0	0	0
BREAST	MA29	4	4	0	4
BREAST	MA31	652	271	645	645
BREAST	MA32	3649	2946	2566	3098
BREAST	MA33	300	184	292	293
BREAST	MA38	180	130	171	171
BREAST	MA39	Open Trial	1019	906	1243
BREAST	MA40	Open Trial	81	98	175
BREAST	MA5	716	599	671	677
BREAST	MAP3	4560	31	82	89
BREAST	MAP3B	238	0	0	0

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
BREAST	MA12	698	5	503
BREAST	MA14	667	5	388
BREAST	MA17	5187	1	23
BREAST	MA17B	226	0	0
BREAST	MA17L	347	0	0
BREAST	MA17R	1918	1	6
BREAST	MA20	1832	16	1064
BREAST	MA21	2104	27	1084
BREAST	MA22	93	3	40
BREAST	MA24	160	0	0
BREAST	MA25	3	0	0
BREAST	MA26	26	0	0
BREAST	MA27	7576	79	3610
BREAST	MA27B	497	0	0
BREAST	MA29	4	0	0
BREAST	MA31	652	10	486
BREAST	MA32	3649	41	2609
BREAST	MA33	300	1	9
BREAST	MA38	180	1	27
BREAST	MA39	Open Trial	1	2
BREAST	MA40	Open Trial	0	0
BREAST	MA5	716	9	597
BREAST	MAP3	4560	1	1
BREAST	MAP3B	238	0	0

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
BREAST	MA12	698	0	0	0	0	0	280	0	0
BREAST	MA14	667	0	0	0	0	1	494	0	0
BREAST	MA17	5187	1	0	0	0	1	0	0	0
BREAST	MA17B	226	0	0	0	0	0	221	217	0
BREAST	MA17L	347	0	0	0	0	0	0	1	0
BREAST	MA17R	1918	637	0	36	0	0	0	0	0
BREAST	MA20	1832	0	0	0	0	0	0	0	0
BREAST	MA21	2104	0	0	0	0	1	2	0	0
BREAST	MA22	93	0	0	0	0	0	0	0	0
BREAST	MA24	160	0	0	0	0	0	0	0	0
BREAST	MA25	3	0	0	0	0	0	0	0	0
BREAST	MA26	26	0	0	0	0	0	0	0	0
BREAST	MA27	7576	3592	0	5038	0	5423	7	0	0
BREAST	MA27B	497	0	0	0	0	0	430	0	0
BREAST	MA29	4	4	0	0	0	4	4	0	0
BREAST	MA31	652	18	0	359	0	483	487	0	0
BREAST	MA32	3649	3397	0	12	0	3603	3397	0	0
BREAST	MA33	300	0	0	0	0	0	0	0	0
BREAST	MA38	180	180	0	0	0	179	140	0	0
BREAST	MA39	Open Trial	1345	0	0	0	1332	0	1	0
BREAST	MA40	Open Trial	186	0	0	0	203	0	0	0
BREAST	MA5	716	0	0	0	0	0	0	0	0
BREAST	MAP3	4560	4143	0	547	0	5	4330	0	0
BREAST	MAP3B	238	0	0	0	0	1	235	0	0